Onco-hematology
#ASCO22 – RCT: Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-Cell Lymphoma.
6 Jun, 2022 | 11:16h | UTCIbrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
#ASCO22 – RCT: Triplet therapy, transplantation, and maintenance until progression in myeloma.
6 Jun, 2022 | 11:06h | UTCTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo
— NEJM (@NEJM) June 5, 2022
#ASCO22 – Phase 1-2 single-arm study: Teclistamab in relapsed or refractory multiple myeloma.
6 Jun, 2022 | 11:11h | UTCTeclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine
Commentary on Twitter
MajesTEC-1: Teclistamab resulted in a high incidence of deep and durable response in patients with triple-class–exposed relapsed or refractory multiple myeloma. #ASCO22 https://t.co/Nanjob1q7p pic.twitter.com/oqfaiu8MOx
— NEJM (@NEJM) June 5, 2022
Cohort Study: Risk of hematologic cancer in patients with undifferentiated pruritus.
30 May, 2022 | 10:35h | UTCRisk of Hematologic Cancer in Patients With Undifferentiated Pruritus – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Undifferentiated Pruritus Associated with Increased Risk of Hematologic Cancer – HCP Live
Cohort Study: Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
27 May, 2022 | 11:56h | UTCEditorial: Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities
Commentary on Twitter
The natural history of Transthyretin Amyloid Cardiomyopathy (ATTR-CM): disease course and clinical outcome among patients diagnosed with early-stage of disease!#amyloid #heart #failure #cardiac #amyloidosis@escardio @ESC_Journals
https://t.co/uvydC3gisD pic.twitter.com/ooKyjeGVNe
— EHJ Editor-in-Chief (@ehj_ed) May 25, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.
26 May, 2022 | 10:57h | UTCRelated:
Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR
Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer
Second Revision of the International Staging System (R2-ISS) for overall survival in Multiple Myeloma.
26 May, 2022 | 10:34h | UTC
Cohort Study: Risk of venous thromboembolism in men with prostate cancer compared with men in the general population.
25 May, 2022 | 11:01h | UTCNews Release: Men with prostate cancer have a higher risk of serious blood clots – BMJ
Commentary on Twitter
Men with prostate cancer have a 50% higher risk of developing venous thrombosis during the 5 years following their cancer diagnosishttps://t.co/RrYAB5lSrb pic.twitter.com/VGMI7GILgE
— K Pavithran (@drkpavithran) May 24, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile.
23 May, 2022 | 00:41h | UTC
Commentary on Twitter
A transcriptomic primary plasma cell leukaemia classifier comprising 53 genes had a sensitivity of 93% in pts with newly-diagnosed MM. Multivariate analysis confirmed the prognostic performance of this classifier vs the International Staging System: https://t.co/bD45PQG9bl #MMSM
— NatureRevClinOncol (@NatRevClinOncol) April 7, 2022
RCT: Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma.
19 May, 2022 | 10:39h | UTCAddition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary: Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma – Cancer Therapy Adviser
Commentary on Twitter
NEW research— Addition of elotuzumab to lenalidomide and dexamethasone did not improve progression-free survival in patients w/ newly diagnosed, transplantation ineligible multiple myeloma: results of the ph3 ELOQUENT-1 trial #mmsm https://t.co/8O3O6ikCJO pic.twitter.com/qe5V7Om9DN
— The Lancet Haematology (@TheLancetHaem) May 12, 2022
How I Treat series on plasma cell dyscrasias.
18 May, 2022 | 10:31h | UTCEditorial: Introduction to a How I Treat series on plasma cell dyscrasias – Blood
How I treat relapsed multiple myeloma – Blood
How I treat frontline transplantation-eligible multiple myeloma – Blood
RCT: Fixed-duration Ibrutinib-Venetoclax in patients with chronic lymphocytic leukemia and comorbidities.
16 May, 2022 | 01:47h | UTC
Commentary on Twitter
In older patients and/or those with comorbidities with untreated #CLL, treatment with ibrutinib-venetoclax was superior to chlorambucil-obinutuzumab, with fewer events and longer PFS after just over 2 yrs of follow-up. Read about the GLOW trial: https://t.co/gYjksIhp96
#LeuSM pic.twitter.com/aBnpdeKhFO— NEJM Evidence (@NEJMEvidence) May 13, 2022
Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukemia, by subtype, during 2000–14: analysis of individual data from 258 cancer registries in 61 countries.
12 May, 2022 | 10:02h | UTC
Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them.
29 Apr, 2022 | 10:51h | UTC
Commentary on Twitter
🆕💥Review Article @ASHE_Journal
Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them #IDTwitter #medtwitter #TwitteRx #MedEd https://t.co/ToPLQXtC4r pic.twitter.com/pZQWWb3ZSx— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) April 28, 2022
Under a http://creativecommons.org/licenses/by/4.0/ license
Guidelines: Cutaneous lymphomas.
25 Apr, 2022 | 00:38h | UTC
State of the Art Review: Novel treatments in B cell non-Hodgkin’s lymphomas.
22 Apr, 2022 | 09:24h | UTCNovel treatments in B cell non-Hodgkin’s lymphomas – The BMJ
Commentary on Twitter
READ: new State of the Art review on novel treatments in B cell non-Hodgkin’s lymphomas.
Learn about mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in treatment https://t.co/EIri6jDBcv
— The BMJ (@bmj_latest) April 22, 2022
British Guideline for the treatment of chronic lymphocytic leukemia.
21 Apr, 2022 | 10:00h | UTCGuideline for the treatment of chronic lymphocytic leukaemia – British Journal of Haematology
RCT: Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
21 Apr, 2022 | 09:56h | UTCIvosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Ivosidenib and azacitidine showed clinical benefit as compared with placebo and azacitidine in patients with newly diagnosed IDH1-mutated AML, a difficult-to-treat population. https://t.co/6K6mWJdd2V pic.twitter.com/qOwOvHcV4j
— NEJM (@NEJM) April 20, 2022
Pre-transplant EASIX (endothelial activation and stress index) may predict the hazard of sepsis after allogeneic stem cell transplantation.
19 Apr, 2022 | 02:04h | UTCPre-transplant EASIX and sepsis after allogeneic stem cell transplantation – Intensive Care Medicine
Commentary on Twitter
🧪 Endothelial complications major causes of mortality post alloSCT. Pre Tx Endothelial Activation & Stress IndeX EASIX (basic lab data characterizing Tx-associated thrombotic microangiopathy) powerful marker of #sepsis, dysfunctional endothelial response.https://t.co/FRGUGT8L78 pic.twitter.com/VF2wTLCHaM
— Intensive Care Medicine (@yourICM) April 18, 2022
Cohort Study: Non-O blood type is associated with increased risk of venous thromboembolism in patients with cancer.
14 Apr, 2022 | 08:29h | UTCABO blood group type and risk of venous thromboembolism in patients with cancer – Blood Advances (link to abstract – $ for full-text)
Review: Cutaneous manifestations of monoclonal gammopathy.
14 Apr, 2022 | 08:21h | UTCCutaneous manifestations of monoclonal gammopathy – Blood Cancer Journal
Review | Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma.
14 Apr, 2022 | 08:03h | UTC
NCCN Guidelines: CAR T-cell–related toxicities in patients with cancer.
11 Apr, 2022 | 01:32h | UTCRelated:
Reviews: CAR T-Cell Therapy Toxicities and Side Effects
Reviews: CAR T-Cell Therapy Toxicities and Side Effects
Critical Care Management of Chimeric Antigen Receptor T Cell–related Toxicity. Be Aware and Prepared
Reviews: CAR T-Cell Therapy Toxicities and Side Effects
Before-and-after study: Antimicrobial stewardship in high-risk febrile neutropenia patients reduced carbapenem and glycopeptide use and was associated with improved clinical outcomes.
4 Apr, 2022 | 00:49h | UTCRelated:
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology
Commentary from the author on Twitter (thread – click for more)
https://twitter.com/AdrienContejean/status/1508792991917432838
Practice review: Evidence-based and effective management of anemia in palliative care patients.
1 Apr, 2022 | 08:21h | UTC